Adma Biologics Stock Today
| ADMA Stock | USD 6.81 0.07 1.04% |
Performance14 of 100
| Odds Of DistressLess than 13
|
ADMA Biologics is trading at 6.81 as of the 6th of May 2024, a 1.04 percent increase since the beginning of the trading day. The stock's open price was 6.74. ADMA Biologics has less than a 13 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for ADMA Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of April 2024 and ending today, the 6th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of October 2013 | Category Healthcare | Classification Health Care |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. The company has 231.77 M outstanding shares of which 8.11 M shares are presently shorted by private and institutional investors with about 3.32 trading days to cover. More on ADMA Biologics
Moving together with ADMA Stock
| 0.68 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
Moving against ADMA Stock
| 0.82 | RGC | Regencell Bioscience | PairCorr |
| 0.81 | TKNO | Alpha Teknova Financial Report 8th of May 2024 | PairCorr |
| 0.78 | PROCW | Procaps Group SA | PairCorr |
| 0.72 | PROC | Procaps Group SA Report 10th of May 2024 | PairCorr |
| 0.72 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.72 | OM | Outset MedicalInc Trending | PairCorr |
| 0.65 | CYTHW | Cyclo Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
ADMA Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ADMA Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ADMA Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Adam Grossman | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering ADMA Biologics report their recommendations after researching ADMA Biologics' financial statements, talking to executives and customers, or listening in on ADMA Biologics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ADMA Biologics. The ADMA consensus assessment is calculated by taking the average forecast from all of the analysts covering ADMA Biologics. | |||||
ADMA Biologics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ADMA Biologics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ADMA Biologics' financial leverage. It provides some insight into what part of ADMA Biologics' total assets is financed by creditors.
| |||||
ADMA Biologics (ADMA) is traded on NASDAQ Exchange in USA. It is located in 465 State Route 17, Ramsey, NJ, United States, 07446 and employs 624 people. ADMA Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ADMA Biologics's market, we take the total number of its shares issued and multiply it by ADMA Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ADMA Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 231.77 M outstanding shares of which 8.11 M shares are presently shorted by private and institutional investors with about 3.32 trading days to cover.
ADMA Biologics currently holds about 52.42 M in cash with 8.8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check ADMA Biologics Probability Of Bankruptcy
Ownership AllocationADMA Biologics holds a total of 231.77 Million outstanding shares. The majority of ADMA Biologics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ADMA Biologics to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in ADMA Biologics. Please pay attention to any change in the institutional holdings of ADMA Biologics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ADMA Ownership Details
ADMA Stock Price Odds Analysis
What are ADMA Biologics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of ADMA Biologics jumping above the current price in 90 days from now is about 5.11%. The ADMA Biologics probability density function shows the probability of ADMA Biologics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.891. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ADMA Biologics will likely underperform. Additionally, aDMA Biologics has an alpha of 0.2965, implying that it can generate a 0.3 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of ADMA Biologics to move above the current price in 90 days from now is about 5.11 (This ADMA Biologics probability density function shows the probability of ADMA Stock to fall within a particular range of prices over 90 days) .
ADMA Stock Institutional Holders
Institutional Holdings refers to the ownership stake in ADMA Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ADMA Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADMA Biologics' value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 4.6 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3.8 M | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 3.5 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 3.5 M | |
| Millennium Management Llc | 2023-12-31 | 3.5 M | |
| Assenagon Asset Management Sa | 2024-03-31 | 3.3 M | |
| Driehaus Capital Management Llc | 2023-12-31 | 3.3 M | |
| Two Sigma Investments Llc | 2023-12-31 | 3.1 M | |
| Deutsche Bank Ag | 2023-12-31 | 3.1 M | |
| Blackrock Inc | 2023-12-31 | 17.9 M | |
| Vanguard Group Inc | 2023-12-31 | 12.9 M |
ADMA Biologics Historical Income Statement
ADMA Biologics Income Statement is one of the three primary financial statements used for reporting ADMA's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ADMA Biologics revenue and expense. ADMA Biologics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, ADMA Biologics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 248.4 M, whereas Income Before Tax is forecasted to decline to (29.7 M). View More FundamentalsADMA Stock Against Markets
Picking the right benchmark for ADMA Biologics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ADMA Biologics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ADMA Biologics is critical whether you are bullish or bearish towards ADMA Biologics at a given time. Please also check how ADMA Biologics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in ADMA Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
ADMA Biologics Corporate Management
Elected by the shareholders, the ADMA Biologics' board of directors comprises two types of representatives: ADMA Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ADMA. The board's role is to monitor ADMA Biologics' management team and ensure that shareholders' interests are well served. ADMA Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ADMA Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA | CFO VP | Profile | |
| Michael Goldstein | Sr Counsel | Profile | |
| Neal Fitzpatrick | Vice Sales | Profile | |
| Kaitlin Kestenberg | Project Compliance | Profile | |
| Cyndi Tolman | VP Services | Profile | |
| Dr DPS | CoFounder Chairman | Profile |
How to buy ADMA Stock?
Before investing in ADMA Biologics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ADMA Biologics. To buy ADMA Biologics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of ADMA Biologics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase ADMA Biologics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located ADMA Biologics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased ADMA Biologics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ADMA Biologics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ADMA Stock please use our How to Invest in ADMA Biologics guide.
Already Invested in ADMA Biologics?
The danger of trading ADMA Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADMA Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADMA Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADMA Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.13) | Revenue Per Share 1.153 | Quarterly Revenue Growth 0.479 | Return On Assets 0.0451 | Return On Equity (0.20) |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.